Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction
Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.
Vertex Pharmaceuticals reported a 12% increase in third-quarter revenue to $3.44 billion, primarily driven by the adoption of its newer cystic fibrosis drug, Alyftrek. Investors responded positively, with shares climbing approximately 1.5% in pre-market trading. Adjusted earnings remained unchanged, but Vertex is allocating its CF gains towards new launches and the recently completed Crinetics acquisition, which may result in lower profits until these investments yield returns.
Alyftrek is gradually replacing Trikafta as the leading CF treatment, as patients transition to a once-daily regimen from Trikafta's twice-daily dosing. Despite higher net prices, overall CF revenue still increased. While operating income adjusted modestly up by 2%, the company is investing heavily in kidney drug sales, Crinetics, and Journavx through associated launch expenses.
The disparity between revenue growth and adjusted operating income is mainly due to the one-time costs from the Crinetics deal, unaffected by tax considerations. Analysts are cautioned against placing too much emphasis on the revised revenue forecast, as the $50 million mid-range estimate is anticipated to be contributed by the recently acquired Palsonify.
Additionally, Vertex's debt burden has increased due to the deal. Investors should keep an eye on the FDA's November 30 decision on povetacicept for IgA nephropathy, as Vertex is already earmarking resources for its launch. Interim results for VX-670 in myotonic dystrophy will also be disclosed by year-end. For further investment insights, consider The Motley Fool's premium services.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
